论文部分内容阅读
目的:探讨曲尼司特联合缬沙坦治疗难治性IgA肾病的临床效果。方法:选取我院在209-2011年间收治的84例难治性IgA肾病患者,其中,男性44例,年龄在23-51岁之间,女性40例,年龄在25-66岁之间,所有患者均经临床诊断为难治性IgA肾病。将84例患者随机分为两组,观察组45例,对照组39例,观察组患者采用曲尼司特联合缬沙坦治疗,对照组患者则仅采用缬沙坦治疗,对两组患者的治疗情况进行跟踪观察,并记录所得数据。结果:经过治疗,两组患者的病情均有一定程度的改善,84例患者中,观察组45例,显效27例,有效14例,无效4例,有效率为91.1%,对照组39例,显效19例,有效11例,无效9例,有效率为76.9%。结论:在治疗难治性IgA肾病疾病时,采用曲尼司特联合缬沙坦治疗的效果较为显著,对于患者病情的改善帮助较大,值得在临床推广应用。
Objective: To investigate the clinical efficacy of tranilast combined with valsartan in the treatment of refractory IgA nephropathy. Methods: Eighty-four patients with refractory IgA nephropathy were enrolled in our hospital from 209 to 2011. Among them, 44 were males, aged 23-51 years and 40 were females, aged 25-66 years Patients were clinically diagnosed as refractory IgA nephropathy. 84 patients were randomly divided into two groups, 45 cases in the observation group and 39 cases in the control group. The patients in the observation group were treated with tranilast plus valsartan. The patients in the control group were treated with valsartan only. Follow-up observation of treatment, and record the data obtained. Results: After treatment, the patients in both groups improved to some extent. Of 84 patients, 45 cases were observed, 27 cases were markedly effective, 14 cases were effective, 4 cases were ineffective, the effective rate was 91.1%, the control group 39 cases, Effective in 19 cases, effective in 11 cases, ineffective in 9 cases, the effective rate was 76.9%. Conclusion: In the treatment of refractory IgA nephropathy disease, the combination of tranilast and valsartan is more effective, which will help to improve the condition of the patients and is worthy of clinical application.